Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis

SIMPLE SUMMARY: Improving treatment strategies for refractory or relapsed advanced non-small-cell lung cancer (NSCLC) remains a challenge. Efficacy and safety of the immune checkpoint inhibitors (ICIs), nivolumab (Niv) plus atezolizumab (Atz), were compared with those of ramucirumab (Ram) plus docet...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancers (Basel)
Prif Awduron: Ando, Koichi, Manabe, Ryo, Kishino, Yasunari, Kusumoto, Sojiro, Yamaoka, Toshimitsu, Tanaka, Akihiko, Ohmori, Tohru, Ohnishi, Tsukasa, Sagara, Hironori
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2020
Pynciau:
Systematic Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7796092/
https://ncbi.nlm.nih.gov/pubmed/33561074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13010052
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg